Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-early tranexamic acid after subarachnoid hemorrhage
NL-OMON22386Not yet recruiting
- Sponsor
- Academic Medical Center Meibergdreef 9 1105 AZ Amsterdam Tel: 020-5666564 Fax: 020-5669590
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tranexamic acid in subarachnoid hemorrhage (SAH), sponsored by Academic Medical Center Meibergdreef 9 1105 AZ Amsterdam Tel: 020-5666564 Fax: 020-5669590. Primary endpoint: Modified Rankin Scale favourable outcome at 6 months. Planned start Jan 2013; status: not yet recruiting.
02
Drugs
tranexamic acid
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NL-OMON22386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22386.